MI-CP151 was a period 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre examine To guage many intravenous doses of sifalimumab, in Grownup people with dermatomyositis or polymyositis (NCT00533091). Primary demo targets were being To guage the protection and tolerability of sifalimumab in dermatomyositis or polymyositis sufferers, when one of several explora... https://lukashvkwj.blogs100.com/31384083/considerations-to-know-about-sifalimumab